文献速递炎症性肠病

丹麦炎症性肠病患者中免疫介导炎症性疾病的发生率

Incidence of Immune-Mediated Inflammatory Diseases Among Patients With Inflammatory Bowel Diseases in Denmark.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-03-29

丹麦全国性队列研究纳入2007至2016年诊断的14377例炎症性肠病(IBD)患者及71885例对照,随访至2016年、移民或死亡。22.5%的IBD患者共患至少1种免疫介导炎症性疾病(IMID),多数IMID发生于IBD起病前。英夫利西单抗治疗与IMID风险降低相关,CD起病后发生IMID与手术风险升高相关。

要点

  • 22.5%的IBD患者共患至少1种IMID,其中80.3%的IMID发生于IBD起病前。
  • 英夫利西单抗治疗与CD和UC患者发生IMID风险降低相关。
  • CD起病后发生IMID与手术风险升高相关(aOR 2.30),UC中无此关联。

核心结论

  • 丹麦全国性研究中,22.5%的IBD患者共患至少1种IMID。
  • IMID共患增加CD患者的手术风险。

研究设计与样本

  • 丹麦全国性队列研究,纳入2007年至2016年诊断的IBD患者14377例(含CD或UC),匹配无IBD的普通人群对照71885例。
  • 所有队列成员从出生随访至2016年、移民或死亡。
  • 通过丹麦国家患者登记和药品统计登记评估IMID的发生。

主要发现

  • 3235例IBD患者(22.5%)同时诊断IMID,其中2600例(80.3%)的IMID发生于IBD起病前。
  • 最常见的IMID为银屑病、哮喘、1型糖尿病和虹膜睫状体炎。
  • 英夫利西单抗治疗的CD患者发生IMID风险降低(aOR 0.52;95% CI 0.34-0.81),UC患者亦降低(aOR 0.47;95% CI 0.29-0.76)。
  • CD起病后发生IMID的患者手术风险升高(aOR 2.30;95% CI 1.46-4.20),UC中未见此关联。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: It is not clear whether the co-occurrence of immune-mediated inflammatory diseases (IMIDs) affects the course of inflammatory bowel diseases (IBD). We investigated the occurrence of IMIDs in relation to onset of IBD and the effects of concurrent IMIDs on IBD outcomes in a nationwide study of the Danish population. METHODS: We used a nationwide cohort of all individuals diagnosed with IBD, including Crohn's disease (CD) or ulcerative colitis (UC), in Denmark from 2007 through 2016 (n = 14,377). Patients were match with individuals without IBD from the general population (controls, n = 71,885). All cohort members were followed from birth until 2016, their migration, or their death. The occurrence of IMIDs was assessed using the Danish national patient register and Registry of Medicinal Products Statistics. RESULTS: A total of 3,235 patients with a diagnosis of IBD (22.5%) has also received a diagnosis of an IMID; most IMIDs occurred before the onset of IBD (n = 2,600, 80.3%). The most common IMIDs observed were psoriasis, asthma, type 1 diabetes, and iridocyclitis. Patients with IBD treated with infliximab were at reduced risk of developing IMIDs (CD adjusted odds ratio [aOR], 0.52; 95% CI, 0.34-0.81 and UC aOR, 0.47; 95% CI, 0.29-0.76). Co-occurrence of IMIDs increased the risk of surgery in patients with CD that developed IMIDs after CD onset (aOR, 2.30; 95% CI, 1.46-4.20) but not in UC. CONCLUSIONS: In a nationwide study of the Danish population, 22.5% of patients with IBD also had at least 1 concurrent IMID. Co-occurrence of IMIDs increased the risk of surgery in patients with CD.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Burisch J, Jess T, Egeberg A, et al. Incidence of Immune-Mediated Inflammatory Diseases Among Patients With Inflammatory Bowel Diseases in Denmark. Clin Gastroenterol Hepatol. 2019. PMID: 30936024. doi:10.1016/j.cgh.2019.03.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。